Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 13;25(1):757.
doi: 10.1186/s13063-024-08584-x.

Effects of melatonin supplementation on metabolic parameters, oxidative stress, and inflammatory biomarkers in diabetic patients with chronic kidney disease: study protocol for a double-blind, randomized controlled trial

Sara Sadeghi  1 , Monir Sadat Hakemi  2 , Fatemeh Pourrezagholie  3 , Fatemeh Naeini  1 , Hossein Imani  4 , Hamed Mohammadi  1
Affiliations

Effects of melatonin supplementation on metabolic parameters, oxidative stress, and inflammatory biomarkers in diabetic patients with chronic kidney disease: study protocol for a double-blind, randomized controlled trial

Sara Sadeghi et al. Trials. .

Abstract

Introduction: Chronic kidney disease (CKD) is a pervasive disease of the current century that usually affects the adult population, especially people with diabetes and hypertension. According to the recent studies, inflammation, oxidative stress, apoptosis, and mitochondrial dysfunction are determining risk factors in the pathogenesis of CKD. Melatonin as a strong antioxidant is produced in various tissues including the kidneys. The present clinical trial aims to examine the efficacy of melatonin supplementation on metabolic parameters, oxidative stress, and inflammatory biomarkers in diabetic patients with CKD.

Methods: This is a double-blind, randomized, placebo-controlled clinical study that will be investigated the impacts of melatonin supplementation in diabetic patients with CKD. Laboratory findings will be applied to diagnose diabetic CKD. Forty-eight eligible diabetic subjects with CKD will be selected and randomly assigned to receive 5 mg melatonin tablets or identical placebo twice daily for 10 weeks. Participants will be asked to remain on their usual diet and physical activity. The primary outcome of this study is changes in oxidative stress and inflammatory biomarkers. The secondary outcomes include changes in lipid profile, renal function indicators, fasting blood sugar and serum insulin, systolic and diastolic blood pressure (SBP and DBP), serum phosphorous concentration, sleep quality, body weight, body mass index (BMI), and waist circumference (WC). Statistical analysis will be conducted using the SPSS software (version 25).

Discussion: We hypothesize that melatonin administration may be useful for treating diabetic CKD by modulating oxidative stress, inflammation, regulating lipid metabolism, and increasing insulin sensitivity through different mechanisms. The current trial will exhibit the effects of melatonin, whether negative or positive, on diabetic CKD status.

Ethical aspects: The current trial received approval from Medical Ethics Committee of Tehran University of Medical Sciences, Tehran, Iran (IR.TUMS.SHARIATI.REC.1402.072).

Trial registration: This study had been registered in Iranian Registry of Clinical Trials.

Registration number: IRCT20170202032367N9 on 11 August 2023. https://www.irct.ir/trial/70709 .

Keywords: Chronic kidney disease; Inflammatory biomarkers; Melatonin; Metabolic parameters; Oxidative stress.

PubMed Disclaimer

Conflict of interest statement

Declarations Ethics approval and consent to participate The current trial received approval from Medical Ethics Committee of Tehran University of Medical Sciences, Tehran, Iran (IR.TUMS.SHARIATI.REC.1402.072).Written informed consent will be obtained from participants before participation in the research project. Consent for publication Not applicable-no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author on request. Competing interests The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study flowchart
Fig. 2
Fig. 2
Timeline of the trial
See this image and copyright information in PMC

References

    1. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786–802. - PubMed
    1. Rahmani A, Maleki V, Niknafs B, Tavakoli-Rouzbehani OM, Tarighat-Esfanjani A. Effect of Nigella sativa supplementation on kidney function, glycemic control, oxidative stress, inflammation, quality of life, and depression in diabetic hemodialysis patients: study protocol for a double-blind, randomized controlled trial. Trials. 2022;23(1):1–9. - PMC - PubMed
    1. Nordheim E, Jenssen TG. Chronic kidney disease in patients with diabetes mellitus. Endocr Connect. 2021;10(5):R151–9. - PMC - PubMed
    1. Oshima M, Toyama T, Haneda M, Furuichi K, Babazono T, Yokoyama H, et al. Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes. PLoS One. 2018;13(8):e0201535. - PMC - PubMed
    1. Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney Dialysis. 2022;2(3):433–42.

Publication types

MeSH terms

LinkOut - more resources